Summary

Eligibility
for people ages 55 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at Torrance, California and other locations
Dates
study started
completion around

Description

Summary

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Official Title

A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events

Details

Keywords

Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome, Type 2 Diabetes Mellitus, The Cleerly CAD Staging System

Eligibility

Locations

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cleerly, Inc.
ID
NCT06112418
Study Type
Interventional
Participants
Expecting 7500 study participants
Last Updated